NUTX trades 79.5% below Wall Street's consensus target of $310.00.
Last 12 months price action with 12-month analyst target path
The base valuation assumes NUTX achieves its forward estimates and maintains a stable P/E multiple of 6.3x. This scenario reflects the blended consensus of 5 Wall Street analysts, balancing both positive catalysts and macroeconomic headwinds over the next 12 months.
As of November 19, 2026, Nutex Health, Inc. (NUTX) has a Wall Street consensus price target of $310.00, based on estimates from 5 covering analysts. With the stock currently trading at $172.74, this represents a potential upside of +79.5%. The company has a market capitalization of $1.19B.
Analyst price targets range from a low of $310.00 to a high of $310.00, representing a 0% spread in expectations. The median target of $310.00 aligns closely with the consensus average. The tight target dispersion indicates high conviction among analysts.
The current analyst consensus rating is Buy, with 5 analysts rating the stock as a Buy or Strong Buy,0 rating it Hold, and 0 rating it Sell or Strong Sell. This overwhelmingly bullish sentiment suggests analysts see significant catalysts for upside ahead.
From a valuation perspective, NUTX trades at a trailing P/E of 7.4x and forward P/E of 6.3x. Analysts expect EPS to grow +17.0% over the next year.
Our proprietary valuation model, which blends historical multiples with forward estimates, suggests a base-case price target of $152.88, with bear and bull scenarios of $96.32 and $201.44 respectively. Model confidence stands at 44/100, suggesting limited visibility into future performance.
| Company | Market Cap | Price | Target | Upside Potential | Rating | Fwd P/E | Analysts |
|---|---|---|---|---|---|---|---|
ADUSAddus HomeCare Corporation | $2.3B | $120.85 | $128.75 | +6.5% | Buy | 17.1x | 18 |
AMSFAMERISAFE, Inc. | $354M | $18.93 | $33.50 | +77.0% | Buy | 10.1x | 6 |
UHSUniversal Health Services, Inc. | $11.3B | $186.07 | $193.13 | +3.8% | Hold | 8.3x | 44 |
THCTenet Healthcare Corporation | $23.4B | $271.34 | $289.00 | +6.5% | Buy | 12.0x | 32 |
CYHCommunity Health Systems, Inc. | $262M | $1.86 | $2.94 | +58.1% | Hold | — | 37 |
HCAHCA Healthcare, Inc. | $103.1B | $476.35 | $463.12 | -2.8% | Buy | 15.8x | 46 |
SGRYSurgery Partners, Inc. | $3.5B | $26.96 | $23.50 | -12.8% | Buy | 75.9x | 23 |
USPHU.S. Physical Therapy, Inc. | $1.5B | $95.43 | $90.00 | -5.7% | Buy | 33.5x | 13 |
MCKMcKesson Corporation | $126.6B | $1084.43 | $983.13 | -9.3% | Buy | 24.3x | 31 |
CAHCardinal Health, Inc. | $65.2B | $278.32 | $279.33 | +0.4% | Buy | 22.1x | 33 |
Quick answers to the most common questions about buying NUTX stock.
The consensus Wall Street price target for NUTX is $310, representing 79.5% upside from the current price of $172.74. With 5 analysts covering the stock, this strong upside suggests significant value not yet reflected in today's share price.
NUTX has a consensus rating of "Buy" based on 5 Wall Street analysts. The rating breakdown is predominantly bullish, with 5 Buy/Strong Buy ratings. The consensus 12-month price target of $310 implies 79.5% upside from current levels.
With a forward P/E of 6.3121x, NUTX trades at a relatively low valuation. The consensus target of $310 implies 79.5% appreciation, suggesting meaningful undervaluation.
The most bullish Wall Street analyst has a price target of $310 for NUTX, while the most conservative target is $310. The consensus of $310 represents the median expectation. Our quantitative valuation model projects a bull case target of $201 based on optimistic growth and margin assumptions. These targets typically reflect 12-month expectations.
NUTX is moderately covered, with 5 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 5 have Buy ratings, 0 recommend Hold, and 0 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
The 12-month NUTX stock forecast based on 5 Wall Street analysts shows a consensus price target of $310, with estimates ranging from $310 (bear case) to $310 (bull case). The median consensus rating is "Buy". Our proprietary valuation model produces a base case fair value of $153, with bear/bull scenarios of $96/$201.
Our quantitative valuation model calculates NUTX's fair value at $153 (base case), with a bear case of $96 and bull case of $201. The model uses discounted cash flow analysis, historical growth rates, and margin mean-reversion to project FY+2 earnings, then applies an appropriate P/E multiple. The model confidence score is 44/100.
NUTX trades at a forward P/E ratio of 6.3x based on next-twelve-months earnings estimates compared to a trailing P/E of 7.4x. The lower forward P/E indicates analysts expect earnings growth. A forward P/E is useful for comparing valuations when earnings are expected to change significantly.
Wall Street analysts are very optimistic on NUTX, with a "Buy" consensus rating and $310 price target (79.5% upside). 5 of 5 analysts rate it Buy or Strong Buy. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
NUTX analyst price targets range from $310 to $310, a 0% tight range reflecting strong analyst consensus. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $310 consensus represents the middle ground. Our model's $96-$201 range provides an independent fundamental perspective.
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.